MEIS1 and myeloid leukemia: The small molecule CCI-006 was described as a novel inhibitor of mixed lineage leukemia (MLL)-rearranged, and CALM-AF10 translocated myeloid leukemia cells by targeting a metabolic vulnerability in a subset of low HIF1alpha/low MEIS1-expressing MLL-rearranged leukemia cells that present more glycolytic metabolic phenotype [63].